Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Duesseldorf – page 2

2 009 clinical trials in Duesseldorf, Germany across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Duesseldorf at a glance
2 009
clinical trials
  • Research sites5
Type of trial
Recruitment status
Quick filters

2 009 trials in Duesseldorf

Open in trial search

Obesity+1

Recruiting

Efficacy and Safety of Once‑Daily Oral ASC30 in Adults with Obesity or Overweight: A Phase III Randomized Placebo‑Controlled Trial

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ASC30 sodium
  • Sponsor:Ascletis Pharma (China) Co. Ltd.

Diabetes mellitus+2

Recruiting

A Phase III Study of ASC30 Sodium for Weight Loss in Adults with Obesity or Overweight and Type 2 Diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ASC30 sodium
  • Sponsor:Ascletis Pharma (China) Co. Ltd.

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

A Phase 3 Randomized Study of Rozanolixizumab for Safety and Efficacy in Adults with Ocular Myasthenia Gravis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Rozanolixizumab
  • Sponsor:UCB Biopharma

Graves' disease

Recruiting

Phase 3 Randomized Placebo‑Controlled Study of Efgartigimod Alfa in Adults with Graves’ Disease Inadequately Controlled by Antithyroid Drugs

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

A Phase III Randomized Double‑Blind Study of Elecoglipron for Adults with Type 2 Diabetes on Insulin

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

A study to assess the effect of elecoglipron alone and in combination with dapagliflozin on blood sugar control in adults with Type 2 diabetes

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

A Phase III Study of Elecoglipron Compared with Semaglutide for Adults with Type 2 Diabetes Mellitus

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Narcolepsy

Recruiting

Efficacy and Safety of ALKS 2680 and Alixorexton in Adults with Narcolepsy Type 1

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ALKS 2680
  • Sponsor:Alkermes Inc.

Study of lunsekimig versus placebo in adults with inadequately controlled eosinophilic COPD

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A Phase 3 Randomized Study of mRNA‑4157 plus Pembrolizumab as Adjuvant Therapy in Patients with Completely Resected Stage I Non‑Small Cell Lung Cancer

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Duesseldorf

What the registry says about research in the country

01 Oncology and Hematologic Malignancies

In Düsseldorf, a large share of trials focuses on cancer research and blood cancers, with studies in breast cancer, colorectal cancer, prostate cancer, multiple myeloma, and leukemia. These trials are mainly testing new treatment combinations, improving post-surgery care, and exploring ways to delay or prevent recurrence.

  • Breast cancer and triple-negative breast cancer research
  • Colorectal cancer, prostate cancer, and other solid tumors
  • Multiple myeloma, lymphoma, AML, and MDS
  • Testing new therapy strategies and improving treatment outcomes

This field is especially active across the city’s research sites, reflecting a strong interest in both common and hard-to-treat malignancies.

02 Dermatology and Hair Disorders

Another important area is skin and connective tissue disease research, including studies on psoriasis, actinic keratosis, androgenetic alopecia, and facial line treatments. These trials are mainly aimed at evaluating new topical or injectable therapies and improving visible symptom control.

  • Moderate to severe plaque psoriasis
  • Actinic keratosis of the face or scalp
  • Androgenetic alopecia in men and women
  • Facial line and cosmetic treatment studies

Several of these studies are designed to compare active treatment with control care and help refine everyday dermatologic treatment options.

03 Digestive and Liver Diseases

Trials in digestive system diseases and virus diseases include research on chronic hepatitis D, metabolic dysfunction-associated steatotic liver disease, and advanced cancers involving the pancreas, colon, and bile ducts. The main goal is to improve treatment effectiveness and support better disease control in difficult liver and gastrointestinal conditions.

  • Chronic hepatitis D infection
  • Metabolic dysfunction-associated steatotic liver disease
  • Pancreatic, colon, and cholangiocarcinoma studies
  • Testing new therapies and surgery-related strategies

These studies highlight a strong focus on therapies for chronic liver illness and advanced abdominal cancers.

04 Neurology and Multiple Sclerosis

Research in nervous system diseases includes trials for multiple sclerosis and other neurological conditions, with an emphasis on long-term safety and treatment benefit. In Düsseldorf, these studies are helping assess whether newer immune-based approaches can better support patients over time.

  • Relapsing multiple sclerosis
  • Progressive multiple sclerosis
  • Broader nervous system disease research
  • Evaluating treatment safety and durability

This area reflects ongoing interest in therapies that may offer steadier disease control with acceptable tolerability.

05 Pediatric and Adolescent Conditions

Pediatric trials cover serious conditions such as high-risk neuroblastoma, acute lymphoblastic leukemia, and respiratory distress in preterm infants. These studies aim to improve survival, reduce complications, and support better long-term outcomes in children and young people.

  • High-risk neuroblastoma
  • Ph+ and ABL-class B-cell acute lymphoblastic leukemia
  • Respiratory distress syndrome in preterm infants
  • Testing more effective treatment and prevention approaches

These trials bring together cancer care and neonatal research, showing a wide pediatric research footprint in the city.

06 Hematology and Bone Marrow Disorders

Several studies address hemic and lymphatic diseases, especially myelodysplastic syndromes, anemia, and refractory hematologic malignancies. The purpose is to find better ways to restore blood counts, improve transfusion independence, and treat patients whose disease has returned or no longer responds to standard therapy.

  • Lower-risk myelodysplastic syndromes
  • Anemia linked to marrow disorders
  • Relapsed or refractory mantle cell lymphoma
  • Evaluating new blood cancer treatments

This research area is particularly important for patients with limited treatment options and persistent blood-related symptoms.

07 Endocrine and Metabolic Research

Düsseldorf also hosts trials in hormonal diseases and nutritional and metabolic diseases, including work on hair loss linked to hormonal imbalance and liver-related metabolic disorders. These studies are designed to test treatment effectiveness and improve symptom management in conditions that often affect quality of life.

  • Hormone-related hair loss
  • Metabolic liver disease
  • Treatment studies in endocrine and metabolic care
  • Assessing benefit and safety of newer therapies

These trials connect chronic metabolic care with visible, patient-centered outcomes.

08 Immunology and Infectious Disease-Related Research

The city’s trial portfolio includes immune system disease research and studies linked to virus diseases, especially where immune pathways affect chronic illness or cancer care. Researchers are exploring new treatment options that may improve control of persistent viral infection and immune-driven disease.

  • Chronic hepatitis D
  • Immune-related treatment strategies
  • Conditions involving chronic inflammation and infection
  • Evaluating newer immune-targeted therapies

This work shows how immunology and virology often overlap in modern clinical research.

09 Diagnostic Imaging and Research Tools

A smaller but important part of the research landscape involves diagnostic techniques and equipment, including studies that assess how well advanced imaging can identify disease and guide care. These trials are focused on improving diagnosis and helping clinicians distinguish between disease subtypes more accurately.

  • Prostate cancer imaging and diagnosis
  • Evaluating PET-based diagnostic performance
  • Improving disease classification
  • Supporting earlier and more precise diagnosis

In Düsseldorf, diagnostic research complements the treatment studies by strengthening the tools used to identify and monitor disease.

10 Respiratory and Early-Life Health

Trials in respiratory tract diseases include research aimed at improving outcomes for preterm infants with breathing problems early in life. The focus is on prevention and better long-term lung function, with the goal of reducing complications that can affect childhood development.

  • Respiratory distress syndrome in premature babies
  • Early intervention and prevention strategies
  • Long-term lung health
  • Supporting better outcomes in neonatal care

This area links specialized newborn care with research designed to improve later respiratory health.

11 Broad Experimental and Translational Studies

Some trials in Düsseldorf span advanced solid tumors and other difficult-to-treat conditions, reflecting a broad translational research effort. These studies are often designed to test whether new therapies can produce meaningful disease control in patients with limited standard options.

  • Advanced solid tumors
  • Mixed oncology populations
  • Early evaluation of promising therapies
  • Exploring anti-tumor activity and safety

This part of the research landscape supports the development of new approaches across multiple cancer types.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.